메뉴 건너뛰기




Volumn 74, Issue 6, 2007, Pages 891-897

Allosteric effects of antagonists on signalling by the chemokine receptor CCR5

Author keywords

35S GTP S binding; Antagonists; Chemokine receptor (CCR5); Chemokines; HIV; Receptor internalisation

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MONOCYTE CHEMOTACTIC PROTEIN 2; RANTES; SULFUR 35; UK 396794; UK 438235; UNCLASSIFIED DRUG;

EID: 34547691003     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.06.032     Document Type: Article
Times cited : (14)

References (29)
  • 1
    • 0029986131 scopus 로고    scopus 로고
    • Molecular cloning and functional expression of a new human CC-chemokine receptor gene
    • Samson M., Labbe O., Mollereau C., Vassart G., and Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 35 (1996) 3362-3367
    • (1996) Biochemistry , vol.35 , pp. 3362-3367
    • Samson, M.1    Labbe, O.2    Mollereau, C.3    Vassart, G.4    Parmentier, M.5
  • 2
    • 0030018156 scopus 로고    scopus 로고
    • CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1
    • Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 (1996) 1955-1958
    • (1996) Science , vol.272 , pp. 1955-1958
    • Alkhatib, G.1    Combadiere, C.2    Broder, C.C.3    Feng, Y.4    Kennedy, P.E.5    Murphy, P.M.6
  • 3
    • 0005014748 scopus 로고    scopus 로고
    • The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
    • Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P.D., et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85 (1996) 1135-1148
    • (1996) Cell , vol.85 , pp. 1135-1148
    • Choe, H.1    Farzan, M.2    Sun, Y.3    Sullivan, N.4    Rollins, B.5    Ponath, P.D.6
  • 4
    • 0030604727 scopus 로고    scopus 로고
    • A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors
    • Doranz B.J., Rucker J., Yi Y., Smyth R.J., Samson M., Peiper S.C., et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85 (1996) 1149-1158
    • (1996) Cell , vol.85 , pp. 1149-1158
    • Doranz, B.J.1    Rucker, J.2    Yi, Y.3    Smyth, R.J.4    Samson, M.5    Peiper, S.C.6
  • 5
    • 15844389650 scopus 로고    scopus 로고
    • HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
    • Dragic T., Litwin V., Allaway G.P., Martin S.R., Huang Y., Nagashima K.A., et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381 (1996) 667-673
    • (1996) Nature , vol.381 , pp. 667-673
    • Dragic, T.1    Litwin, V.2    Allaway, G.P.3    Martin, S.R.4    Huang, Y.5    Nagashima, K.A.6
  • 7
    • 0036464697 scopus 로고    scopus 로고
    • Pathways for internalization and recycling of the chemokine receptor CCR5
    • Mueller A., Kelly E., and Strange P.G. Pathways for internalization and recycling of the chemokine receptor CCR5. Blood 99 (2002) 785-791
    • (2002) Blood , vol.99 , pp. 785-791
    • Mueller, A.1    Kelly, E.2    Strange, P.G.3
  • 8
    • 0033567969 scopus 로고    scopus 로고
    • CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist
    • Blanpain C., Migeotte I., Lee B., Vakili J., Doranz B.J., Govaerts C., et al. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood 94 (1999) 1899-1905
    • (1999) Blood , vol.94 , pp. 1899-1905
    • Blanpain, C.1    Migeotte, I.2    Lee, B.3    Vakili, J.4    Doranz, B.J.5    Govaerts, C.6
  • 9
    • 43949153331 scopus 로고
    • CC chemokines in allergic inflammation
    • Baggiolini M., and Dahinden C.A. CC chemokines in allergic inflammation. Immunol Today 15 (1994) 127-133
    • (1994) Immunol Today , vol.15 , pp. 127-133
    • Baggiolini, M.1    Dahinden, C.A.2
  • 12
    • 30744447460 scopus 로고    scopus 로고
    • Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
    • Fatkenheuer G., Pozniak A.L., Johnson M.A., Plettenberg A., Staszewski S., Hoepelman A.I., et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11 (2005) 1170-1172
    • (2005) Nat Med , vol.11 , pp. 1170-1172
    • Fatkenheuer, G.1    Pozniak, A.L.2    Johnson, M.A.3    Plettenberg, A.4    Staszewski, S.5    Hoepelman, A.I.6
  • 13
    • 15744391870 scopus 로고    scopus 로고
    • The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor
    • Watson C., Jenkinson S., Kazmierski W., and Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 67 (2005) 1268-1282
    • (2005) Mol Pharmacol , vol.67 , pp. 1268-1282
    • Watson, C.1    Jenkinson, S.2    Kazmierski, W.3    Kenakin, T.4
  • 14
    • 27644510382 scopus 로고    scopus 로고
    • Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
    • Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49 (2005) 4721-4732
    • (2005) Antimicrob Agents Chemother , vol.49 , pp. 4721-4732
    • Dorr, P.1    Westby, M.2    Dobbs, S.3    Griffin, P.4    Irvine, B.5    Macartney, M.6
  • 15
    • 0037019271 scopus 로고    scopus 로고
    • Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity
    • Palani A., Shapiro S., Josien H., Bara T., Clader J.W., Greenlee W.J., et al. Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity. J Med Chem 45 (2002) 3143-3160
    • (2002) J Med Chem , vol.45 , pp. 3143-3160
    • Palani, A.1    Shapiro, S.2    Josien, H.3    Bara, T.4    Clader, J.W.5    Greenlee, W.J.6
  • 16
    • 13044256383 scopus 로고    scopus 로고
    • A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
    • Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 96 (1999) 5698-5703
    • (1999) Proc Natl Acad Sci USA , vol.96 , pp. 5698-5703
    • Baba, M.1    Nishimura, O.2    Kanzaki, N.3    Okamoto, M.4    Sawada, H.5    Iizawa, Y.6
  • 18
    • 71849104860 scopus 로고
    • Protein measurement with the folin phenol reagent
    • Lowry O., Rosebrough N., Farr A., and Randall R. Protein measurement with the folin phenol reagent. J Biol Chem 193 (1951) 265-275
    • (1951) J Biol Chem , vol.193 , pp. 265-275
    • Lowry, O.1    Rosebrough, N.2    Farr, A.3    Randall, R.4
  • 19
    • 28244469774 scopus 로고    scopus 로고
    • Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human
    • Napier C., Sale H., Mosley M., Rickett G., Dorr P., Mansfield R., et al. Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol 71 (2005) 163-172
    • (2005) Biochem Pharmacol , vol.71 , pp. 163-172
    • Napier, C.1    Sale, H.2    Mosley, M.3    Rickett, G.4    Dorr, P.5    Mansfield, R.6
  • 21
    • 0031465316 scopus 로고    scopus 로고
    • Inverse agonism and the regulation of receptor number
    • Milligan G., and Bond R.A. Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci 18 (1997) 468-474
    • (1997) Trends Pharmacol Sci , vol.18 , pp. 468-474
    • Milligan, G.1    Bond, R.A.2
  • 22
    • 1642495639 scopus 로고    scopus 로고
    • Efficacy as a vector: the relative prevalence and paucity of inverse agonism
    • Kenakin T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol 65 (2004) 2-11
    • (2004) Mol Pharmacol , vol.65 , pp. 2-11
    • Kenakin, T.1
  • 24
    • 32944470681 scopus 로고    scopus 로고
    • The development of an europium-GTP assay to quantitate chemokine antagonist interactions for CXCR4 and CCR5
    • Labrecque J., Anastassov V., Lau G., Darkes M., Mosi R., and Fricker S.P. The development of an europium-GTP assay to quantitate chemokine antagonist interactions for CXCR4 and CCR5. Assay Drug Dev Technol 3 (2005) 637-648
    • (2005) Assay Drug Dev Technol , vol.3 , pp. 637-648
    • Labrecque, J.1    Anastassov, V.2    Lau, G.3    Darkes, M.4    Mosi, R.5    Fricker, S.P.6
  • 25
    • 0035940445 scopus 로고    scopus 로고
    • SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo
    • Strizki J.M., Xu S., Wagner N.E., Wojcik L., Liu J., Hou Y., et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 98 (2001) 12718-12723
    • (2001) Proc Natl Acad Sci USA , vol.98 , pp. 12718-12723
    • Strizki, J.M.1    Xu, S.2    Wagner, N.E.3    Wojcik, L.4    Liu, J.5    Hou, Y.6
  • 26
    • 27144491979 scopus 로고    scopus 로고
    • Analysis of allosterism in functional assays
    • Ehlert F.J. Analysis of allosterism in functional assays. J Pharmacol Exp Ther 315 (2005) 740-754
    • (2005) J Pharmacol Exp Ther , vol.315 , pp. 740-754
    • Ehlert, F.J.1
  • 27
    • 33751183557 scopus 로고    scopus 로고
    • Determining the potency and molecular mechanism of action of insurmountable antagonists
    • Kenakin T., Jenkinson S., and Watson C. Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 319 (2006) 710-723
    • (2006) J Pharmacol Exp Ther , vol.319 , pp. 710-723
    • Kenakin, T.1    Jenkinson, S.2    Watson, C.3
  • 28
    • 34547714401 scopus 로고    scopus 로고
    • Antagonism of the CCR5 receptor by SCH-C leads to elevated beta-chemokine levels and receptor expression in chronically treated PBMC cultures
    • February 24-28, 2002, Seattle
    • Xu L., Wojcik N., and Strizki J.M. Antagonism of the CCR5 receptor by SCH-C leads to elevated beta-chemokine levels and receptor expression in chronically treated PBMC cultures. Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections. February 24-28, 2002, Seattle (2002)
    • (2002) Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections
    • Xu, L.1    Wojcik, N.2    Strizki, J.M.3
  • 29
    • 34547705105 scopus 로고    scopus 로고
    • Pharmacogenetic analysis of polymorphisms in the chemokine receptors CCR5 and CCR2 in the clinical development of a CCR5 antagonist (UK-427,857) for the treatment of HIV/AIDS
    • February 20, 2004, Washington
    • Penny M., Myrand S., Lin C., Boucher M., Man M., and James I. Pharmacogenetic analysis of polymorphisms in the chemokine receptors CCR5 and CCR2 in the clinical development of a CCR5 antagonist (UK-427,857) for the treatment of HIV/AIDS. FDA Science Symposium. February 20, 2004, Washington (2004)
    • (2004) FDA Science Symposium
    • Penny, M.1    Myrand, S.2    Lin, C.3    Boucher, M.4    Man, M.5    James, I.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.